BioAtla

About:

BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform.

Website: http://bioatla.com

Top Investors: Deerfield, Cormorant Asset Management, Janus Henderson Investors, Farallon Capital Management, Vivo Capital

Description:

BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow them to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment, even when the target is also found in normal tissue, not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.